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 Gadolinium -doped iron oxide nanoparticles induced magnetic field 
hyperthermia combined with radiotherapy increases tumor response 
by vascular disruption and improved oxygenation 
The gadolinium-doped iron oxide nanoparticles (GdIONP) with greater specific 
power adsorption rate (SAR) than Fe3O4 was developed and its potential 
application in tumor therapy and particle tracking were demonstrated in 
transgenic adenocarcinoma of the mouse prostate C1 (TRAMP-C1) tumors. The 
GdIONPs accumulated in tumor region during the treatment could be clearly 
tracked and quantified by T2-weighted MR imaging. The therapeutic effects of 
GdIONP-mediated hyperthermia alone or in combination with radiotherapy were 
also evaluated. A significant increase in the tumor growth was observed 
following the treatment of thermotherapy only group (2.5 days), radiation therapy 
only group (4.5 days), and the combined radio-thermotherapy group (10 days). 
Immunohistochemical staining revealed a reduced hypoxia region with vascular 
disruption and extensive tumor necrosis following the combined radio-
thermotherapy. These results indicate that GdIONP-mediated hyperthermia can 
improve the efficacy of radiotherapy by its dual functions in high temperature 
(temperature greater than 45 degree C)-mediated thermal ablation and mild-
temperature hyperthermia (MTH) (temperature between 39 ~ 42 °C)-mediated 
reoxygenation. 
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Introduction 
Magnetic nanoparticles are widely used for a variety of biomedical application, 
including targeted delivery of therapeutic agents, hyperthermia treatment of cancers, 
magnetic resonance (MR) imaging, and biomagnetic separation [1-4]. Magnetic 
nanoparticles have been suggested as a suitable mediator in conventional thermotherapy 
for achieving intratumor hyperthermia and reducing side effects [5, 6][7]. Magnetic 
nanoparticles- mediated thermotherapy involves a coupling of an external magnetic 
field to heat the tumor areas surrounding the magnetic particles [8-10]. The magnetic 
particles interact with the magnetic field and dissipate energy to their surroundings, 
causing a heating effect in deep tissues. The mechanisms that the energy is dissipated 
are strongly related to the physical and chemical properties of the particles and can be 
expressed by their specific power adsorption rate (SAR) [11]. We have developed 
gadolinium-doped iron-oxide nanoparticles (GdIONP) with superparamagnetic 
characteristics and a higher SAR value than the reported ones of Fe3O4 by four times 
[12, 13].  Radiation therapy has been employed to treat approximately 50% of various 
cancer patients. The ionizing radiation dosage given to the tumor is determined based 
on the radiosensitivity of the surrounding normal tissue [14]. Therefore, the tolerant 
radiation dose is frequently not sufficient to eliminate all loco-regional reoccurrences or 
cure localized cancers [15].  The success rate of local tumor control by radiation therapy 
is determined primarily by the number of clonogens [16] and their intrinsic cellular 
radioresistance, and the microenvironmental factors such as hypoxia. The hypoxia 
induced by cellular and micro-environmental changes of tumor contribute to tumor 
aggressiveness and resistance to radiation therapy [15, 17]. Several therapeutic 
strategies have been developed to overcome the problem of tumor hypoxia [18]. One of 
the most highly effective therapeutic adjuncts for radiation therapy is mild 
hyperthermia, which provides both direct anti-tumor [19, 20] as well as the 
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microenvironment effects [21, 22]. Several preclinical or clinical studies have 
demonstrated improved responses when tumors were treated with a combination of 
localized hyperthermia and radiotherapy compared with radiotherapy alone [19, 23] 
[24]. However, several issues still need to be resolved before hyperthermia can be 
utilized as a radiation enhancer in routine clinical practices, including a sufficient 
delivery of thermal doses, the heating duration required, and the problem resulted from 
the instability of local temperatures. Nanoparticle-induced magnetic field hyperthermia 
has shown its potential in solving these issues by providing a non-invasive and localized 
treatment. In the previous studies, we have shown the biocompatibility, thermal profile 
under alternating magnetic field and superparamagnetic characters of the GdIONP [12, 
13].  Herein we further demonstrate the effects of GdIONP-induced magnetic field 
hyperthermia combined with a radiotherapy and the interaction mechanism in an 
intramuscular TRAMP-C1 tumor model.  
This study demonstrates that the magnetic nanoparticle-mediated hyperthermia 
caused mixed thermotherapeutic effects such that thermal ablation close to the GdIONP 
localization while mild hyperthermia at a distant was observed. The results suggest that 
GdIONP-induced magnetic field hyperthermia enhances the efficacy of radiation 
therapy by two possible mechanisms: (1) reducing the fraction of hypoxic cells that are 
resistant to radiation cytotoxic effect and (2) inducing localized tumor-specific vascular 
disruption and necrosis. This study also presents a simple approach to incorporate the 
advantages of these two radiation-modifying effects using a single strategy, GdIONP-
mediated hyperthermia. 
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Materials and Methods 
Synthesis of Gd-doped iron oxide nanoparticles 
Gd-doped iron oxide nanoparticles (GdIONP) were synthesised as described by Drake 
et al. [12]. The detailed synthesis and characterisation can be seen in the supplementary 
material associated with this paper. The nanoparticle (NPs) composition was 
Gd0.02Fe2.98O4 as determined by inductive coupled plasma with atomic emission 
spectroscopy (ICP-AES). The nanoparticle (NPs) composition was Gd0.02Fe2.98O4 as 
determined by inductive coupled plasma - atomic emission spectroscopy (ICP-AES). 
The GdIONPs are 13.2 ± 3.1 nm in diameter and superparamagnetic with a 
magnetisation value (Ms) of 65.67 emu g
-1
. The magnetisation curve, X-ray diffraction 
pattern (XRD) and TEM images can be seen in the supplementary material fig S1, S2 
and S3 respectively.  For use in this study the GdIONPs were given a dextran coating.  
To achieve this the nanoparticles were dispersed in deionised water and dextran (10000 
Mw). After ultrasonic mixing, NH4OH was added to bring the pH to 10. The mixture 
was then continuously stirred while being heated to 75 °C and was held at this 
temperature for 75 min. To remove excess dextran the suspension was dialyzed using a 
membrane with a molecular weight cut-off (MWCO) at 10000 Daltons. The suspension 
was then centrifuged at 4000 g for 30 min to remove any large aggregates. Finally, the 
suspension was filtered through a 0.2 m filter. 
Cells and animals 
All experiments were done with the use of 6-to-8-weeks-old male C57BL/6J mice. The 
transgenic adenocarcinoma of the mouse prostate (TRAMP)-C1 prostate cancer cell line 
was derived from transgenic mice with adenocarcinoma of the mouse prostate [25] and 
was purchased from the ATCC (CRL-2730). During the experiments, all mice were 
cared for in accordance with the guidelines approved by the Institutional Animal Care 
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and Use Committee (IACUC) of National Tsing Hua University, Taiwan (approved 
number: IACUC:09705). Tumors were generated by intramuscular injection (i.m.) of 
3*10
6
 viable cells into the thigh. Mice with tumors with 4 to 6 mm in diameter were 
selected and randomly allocated to groups for experimentation (tumor diameter was 
defined as the diameter of tumor-bearing leg – the diameter of control mouse leg, in 
which the diameter is defined as  ((the length of long axis at the tumor region + the 
length of short axis at the tumor region)/2), and the tumor volume in mm
3
 was 
calculated by the formula: volume = 4/3 x 3.1416 x (diameter/2)
3
, in which at least 5 
mice were evaluated at each time point. 
Radiotherapy and Thermotherapy 
The mice were randomly divided into four groups for the different treatments: (1) no 
treatment as control, (2) a single dose radiation therapy (RT) of 25 Gy, (3) twice of the 
40-min GdIONP-mediated thermotherapy (TT)  using magnetic field hyperthermia (500 
Ampere and 200 Gauss ) separated by 16-hour interval, (4) a combined treatment (RT + 
TT) using a 25 Gy radiation therapy followed by a thermotherapy (radio-thermotherapy) 
30 minutes afterward (see supplement Fig. S4). The mice in TT and RT+TT group were 
injected with 0.05ml GdIONP in saline before the magnetic field hyperthermia, and the 
mice in control and RT groups were injected with 0.05ml saline without hyperthermia 
treatment. This combined therapeutic protocol was designed according to the suggested 
best combined sequence [14]. Mice were anesthetized by a mixture of ketamine and 
xylazine and restrained by adhesive tape during irradiation, thermotherapy, and MRI 
imaging. A single dose irradiation of 25 Gy was delivered to the tumor site using 6 MV 
X-rays from a linear accelerator with a dose rate of 2.3 Gy/min and a 1.5 cm bolus on 
the surface, with the rest of body shielded. GdIONP (1 mg) prepared in 0.05 mL saline 
was intratumorally injected into the tumors. The groups receiving TT were then 
 
7 
subjected to an induction heating operated at 52 kHz and 246 Oe. The tumor size was 
then monitored by daily recording the diameter measured by Vernier calliper. For mice 
receiving two injections of either nanoparticles or saline solutions for the blank control 
group, the 1st injection were conducted at the start of treatment or after RT, and the 2nd 
injection were carried out 16 hours after the 1st injection.  The temperature read by the 
thermocouple needle positioned at the tumor core (or injection site) was continuously 
recorded during the magnetic hyperthermia. The effect of comparison among groups 
was made with tumor growth delay that was defined as the time taken for a treated 
tumor to grow to 350 cubic mm after treatment and compared with control.  
Immunohistochemistry and image analysis 
For detecting hypoxia, pimonidazole hydrochloride (Hypoxyprobe-1 Kit; 
Chemicon) was administered as 4 mg in 0.1 mL by intravenous injection (i.v.). One 
hour after administration of the hypoxia reagent [26], the tumors were removed and 
stored in optimal cutting temperature compounds at -80 degree C. For 
immunohistochemical staining, ten-micrometer cryostat sections were fixed in methanol 
at -20 degree C for 10 min and then rehydrated in PBS. Nonspecific binding was 
blocked by incubating the sections in 1% bovine serum albumin in PBS for 30 min. 
Tumor sections were double stained for pimonidazole (PIMO) and CD31. Pimonidazole 
was detected with the mouse antibody (Chemicon) and goat anti-mouse IgGγ1 Alexa 
488 (Invitrogen). For labelling endothelial cells, rat anti-CD31 antibody (BD 
Biosciences) and then a secondary goat anti-rat antibody conjugated with Alexa 594 
(Invitrogen) was utilized. Slides were rinsed in PBS and mounted with ProLong Gold 
antifade reagent with DAPI (P-36931; Invitrogen). Sections stained by standard H&E 
reagent (Merck) were used to identify the necrotic areas.  
Immunofluorescent images from each tumor section were captured with the use 
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of an external digital camera (DXM-1200C; Nikon) on a Nikon fluorescence 
microscope (Nikon Eclipse TE 2000-S). Scanning at X100 magnification yielded 
composite images of endothelial cells with the perfusion marker and pimonidazole. 
Composite images were obtained at X200 or X630 magnification. The images were 
analyzed by Image-Pro version 4 software (Media Cybernetics). Microvascular density 
(MVD) was determined as the number of pixels positive for CD31 divided by the total 
tumor area. Regions of gross necrosis were visually identified on the H&E images and 
were outlined with a multiple-area-of-interest tool to determine the percentage in total 
tumor area. The hypoxia fraction was defined as the area positive for pimonidazole 
divided by the total tumor area (necrosis excluded). Data are presented as means with 
standard deviation. Statistical analyses used GraphPad Prism version 3 (GraphPad 
Software). For all comparisons, assessment of statistical significance was by unpaired t 
tests or one-way ANOVA with significance set at P ≦0.05. 
MR imaging 
All magnetic resonance imaging (MRI) scans were acquired on a 7-T animal MRI 
scanner (Bruker ClinScan 70/30). The imaging parameters for the T1-weighted images 
of pre-GdIONP injection were as follows: repetition time (TR) / echo-time (TE) / Flip 
angle = 600 ms/ 3.81 ms/ 25 degree, slice thickness = 0.5 mm, matrix size = 176 X 256 
and field-of-view (FOV) = 27 X 40 mm. 1 mg GdIONPs in 0.05 mL of saline were 
intratumorally injected. The T1-weighted imaging parameters were used: TR/ TE/ Flip 
angle = 600 ms/ 3.81 ms/ 25 degree, slice thickness = 0.5 mm, matrix size = 176X 256 
and FOV = 34 X 50 mm. T2-weighted images were then acquired to confirm no 
anatomical change after GdIONPs injection. The following parameters were used: TR/ 
TE/ Flip angle = 3140 ms/ 38 ms/ 180 degree, slice thickness = 1 mm, matrix size = 228 
X 320, FOV = 25 X 35 mm. 
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Results 
Combined GdIONPs-mediated hyperthermia with radiation therapy enhances 
tumor growth delay 
In order to assess the influences of GdIONPs-mediated hyperthermia on radiation 
therapy-induced tumor growth delay, the tumor size of individual mouse in each 
treatment group was measured daily by calliper (Figure 1). The tumor growth curve 
shows that the radiotherapy (RT) and thermotherapy (TT) had similar effect on tumor 
growth delay (2.5 and 4.5 days, respectively), while tumor growth were delayed more 
than 10 days by the combined therapy (RT+TT). This result suggests that the GdIONPs-
mediated hyperthermia could significantly increase the efficacy of radiation therapy for 
TRAMP-C1 tumor.  
GdIONP mediated hyperthermia 
The distribution of the injected GdIONPs was investigated using T1 and T2 MRI as 
shown in Figure 2A. Images showed that the injected GdIONPs remained concentrate in 
TRAMP-C1 tumors after the hyperthermia treatment for 10, 30, and 50 minutes. The 
temperature profile (Figure 2B) recorded by thermocouple needle showed that the 
temperature of at the cord of tumor tissue exceeded 45 degree C after hyperthermia 
treatment for more than 40 minutes. The simulated temperature distribution profile 
(Figure 2C) [27]  showed that the tumor temperature decreases 1.5 degree C for each 2 
mm.  This indicates that GdIONP-mediated thermal effect may not be the same at the 
different regions, which depends on the distance to the injection site.  
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Anti-tumor and microenvironmental effects 
Hematoxylin and Eosin (H&E) and PIMO staining were used to examine the 
pattern of necrosis and hypoxia, respectively, of tissues at day 1 and week 1 post 
GdIONP-induced thermotherapy, and the necrotic regions were highlighted by the 
yellow outlines in Figure 3. While there is no regular necrotic pattern in control tumors 
at day 1, the necrotic regions in thermotherapy-treated tissue were mainly located in the 
areas with intensive signal of T2 image (Fig 2A). This is in consistent with our previous 
report that the necrotic region induced by TT was co-localized with GdIONP deposition 
from the analysis obtained by the laser ablation/inductively coupled plasma (LA-ICP-
MS) mapping technique [28]. PIMO staining revealed large continuous hypoxia zones 
surrounding the necrotic regions. When the areas of the necrotic and hypoxic regions 
were calculated (Fig. 3E and 3F), it appeared that the ratios of necrosis and hypoxia in 
the control tumors were increased as the tumors grew. However, the necrotic region was 
significantly increased one day after TT, and the ratio was maintained high for one 
week after treatment. It is worth noting that the ratio of hypoxia was not increased with 
the increase of necrotic region at week one after TT as observed in the control group. 
This supports the hypothesis that two working mechanisms were involved in the 
GdIONP-mediated hyperthermia therapy. In order to better characterize the effect of 
these two working mechanisms, the tissues were counterstained by PIMO for hypoxia 
and CD31 for vessels (Fig. 4A). The CD31 positive cells of the control group were 
randomly distributed all over the tumor, suggesting the vessels were intervened 
throughout the hypoxia and necrosis regions (Fig. 4A). This is consistent with a general 
opinion that the hypoxia and necrosis of growing tumors mainly due to the malfunction 
of tumor vessels [26]. 
In contract, almost no vessels were observed in the necrotic regions at day 1 post 
TT. The microvascular density (MVD) in the non-necrotic regions (Fig. 4B) did not 
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significantly change at day one and week one post TT. This again supports the theory 
that thermal ablation effect took place at regions subject to high temperature and 
resulted in massive vessel disruption and necrosis, while the MTH on the contrary did 
not cause significant impact on vessel numbers. We further evaluated the changes in 
necrosis, hypoxia, and MVD of the tumor specimens for the four experimental groups, 
(control, RT, TT, and RT+TT), at 15 days post treatment despite that the control tumor 
was removed at day 10 due to ethical issue (Fig. 5A). As the inference from the 
previous experiments, the necrosis ratio in tumor of the control group was further 
increased to 44.3% (Fig.5B) while the ratio of hypoxia was maintained at a 15.4% level 
(Fig. 5C). This might be owing to the relative constant MVD at untreated tumors (Fig. 
5D). It should be noted that the necrotic region was excluded from the calculation of 
hypoxia ratio and MVD.  
On the other hand, although the 25 Gy of irradiation (RT group) and the two-
dose 40-min GdIONP-mediated thermotherapy (TT group) produced similar tumor 
growth delay (Fig. 1), they might contribute differently to the changes of necrosis, 
hypoxia, and MVD. The tissues from TT-treated tumors had a higher percentage of 
necrosis, lower percentage of hypoxia, and higher MVD than those in RT-treated 
tissues. This indicates different anti-tumor mechanisms might be involved in RT versus 
TT. The combined radio-thermotherapy had the greatest effect on reducing tumor size 
and brought about higher percentage of necrosis (21.87%, Fig. 5B) and hypoxia (~13%, 
Fig.5C), but mixed results in MVD (Fig. 5D). This indicates a complex interactive 
mechanism between RT and TT.  
 
Discussion 
This study describes the anti-tumor effect and microenvironmental changes after the 
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GdIONP mediated thermotherapy, radiation therapy or combined radio-thermotherapy. 
The results suggest that the combined radio-thermotherapy can significantly inhibit 
tumor growth better than RT or TT alone. The enhancement of radiation therapy by 
GdIONP-mediated thermotherapy resulted from a mixed thermotherapeutic effect, high 
temperature-mediated thermal ablation and mild-temperature hyperthermia (MTH)-
mediated tumor reoxygenation. It has been shown that thermal ablation could lead to 
tumor destruction by direct cell necrosis, coagulation, and protein denaturation [29]. 
The significant increase of necrosis percentage one day after TT and the spatial 
correlation of necrosis pattern and GdIONP distribution tracked by MR imaging support 
the ablation effect of the GdIONP induced hyperthermia (Temperature >45degrees C). 
The dysfunction of the vessel collapsed at GdIONP-concentrated regions was due to the 
thermo-sensitive response of vessels in tumors. The tumor vasculature system is less 
capable in heat dissipation owing to blood flow reduction and therefore is more likely to 
be damaged by hyperthermia [30-32].  Owing to inefficient blood flow and oxygen 
transported by the immature blood vessels the tumor cells reside in an acidic and 
nutrient-deprived environment that confers them greater thermosensitivity. This is the 
main effect contributed by high temperature TT. The effect of TT on vessel networks 
was not so evident when the MVD of non-necrotic area only was used for evaluation. 
However, decrease in the number of vessels and enlargement in vessel diameter were 
observed. It has been suggested that blood flow and perfusion could be increased by 
mild hyperthermia (heating to 39 –  42℃) [14, 31, 33].  Due to the temperature 
gradients induced by the magnetic nanoparticle in hyperthermia (Fig. 2C), a mild 
hyperthermia effects could occur on the periphery of the GdIONP concentrated region. 
The temperature gradient of tumor is - 0.75
 
degree C/mm from the centre of MNPs for 
multi-layer structures such as skin, fat and muscle according to the numerical analysis 
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results of MNPs mediated hyperthermia [27]. MR imaging and laser 
ablation/inductively coupled plasma (LA-ICP-MS) mapping showed that GdIONP were 
localized in the injected site throughout the hyperthermia and remained within an area 
of 3 to 5 mm in diameter inside the tumor for two weeks after TT [28].  The temperature 
at tumor core was more than 45 degree C and decreased from 43 degree C to 40 degree 
C at 2.7 mm to 6.7 mm away from the GdIONPs-deposited region (Fig. 2C). Therefore, 
the periphery of GdIONP concentrated-tumor core might be subject to mild-
hyperthermia. This is possibly the reason that the hypoxia ratio in the TT-treated group 
was the lowest among all four groups after two weeks (Fig. 5C).  It needs to remind that 
the TT was given on day 0.  The histological data that we saw from the samples of week 
2 were a re-growing tumor, of which the microenvironment was affected by the tumor 
microenvironment altered by the TT therapy at day 0.  In opposite to the thermotherapy, 
RT resulted in small and dispersed necrosis areas [26]. The combined radio-
thermotherapy produced both effects thus resulting in large necrotic areas in GdIONP-
concentrated tumor core and small necrosis in the surroundings. This partially explains 
the increased effect on the tumor growth delay (Fig. 1). It also indicated that GdIONP-
mediated hyperthermia and RT might have complementary role in tumor therapy. In 
addition to the reduction in MVD, RT, as TT, it also resulted in increase in vessel 
diameter, which is in consistent with the published results [26, 34]. These results 
demonstrate that TT and RT not only have complementary anti-tumor effect, but also 
result in vessel dilation.  
In this study, the TT was applied after RT since it has been reported that such schedule 
yielded the best enhancement for RT through heat [23]. Hyperthermia acts as a potent 
and selective radiosensitizer by three major possible mechanisms: (1) inhibiting or 
impairing DNA repair, (2) devastating the radioresistant and hypoxic tumor cells, (3) 
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altering the vascular microenvironment [14]. The combination of heat and radiation in a 
clinical regimen will probably be conducted in a fractionated schedule. For clinical 
practice a pronounced treatment could be realised by adjusting the sequence, frequency, 
dosage, duration and the intermittent time for conjointly administering the two 
modalities [35-37]. The combined radio-thermotherapy protocol used in this study 
contributed to the reduction in hypoxia and generated similar vascular patterns as the 
RT alone, indicating the involvement of mild hyperthermia effect implied by the 
observed enhanced effects from the tumor growth curve. 
 
Conclusion 
The GdIONP in this study were demonstrated to have a high SAR value and 
superparamagnetic characteristic [15]. The improved SAR value of this Gd-doped 
system can be translated into improved tumor therapy [16]. The MR imaging and LA-
ICP-MS mapping verified the stability of the nanoparticles with no decomposition 
evident in the tissue and their potential usage as T2 contrast agents [30]. In this study, 
we further demonstrate that GdIONP-mediated thermotherapy delivered mixed 
thermotherapeutic effects, showing thermal ablation in Gd-IONP deposited region and 
mild hyperthermia away from the thermal ablation region. The approach enhances the 
efficacy of radiation therapy by reducing the fraction of hypoxic cells that contribute to 
radiation resistance and by inducing tumor-specific localized vascular disruption and 
necrosis. This study also presents a simple means to combine the advantages of these 
two radiation-modifying effects using a single strategy, GdIONP-mediated 
hyperthermia. The multiple modalities of the GdIONP highlight the potential for 
biomedical application. 
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Figures and Table 
 
 
Fig. 1 Tumor growth curves after various treatments.  Combined therapy 
(RT+TT) has resulted in longer tumor growth delay (~10 days) than the 
radiotherapy (RT, ~4.5 days) or the GdIONP mediated thermotherapy (TT, ~2.5 
days) only. TRAMP-C1 cells (1×10
6
) were injected intramuscularly into the tights 
of male C57BL/6J mice. Mice with a palpable tumor of approximately 60 mm
3
 in 
volume were randomly separated into four groups (n = 5) and were given 2 times 
intratumor injections of GdIONP or saline before thermotherapy. Mice were 
anesthetized before treatments. For the control and RT group, 0.05 ml saline alone 
was injected. For TT and RT+TT group, 1 mg GdIONP prepared in 0.05 ml saline 
was injected. TT group were subjected to induction heating at 52 kHz and 246 Oe.  
In the end of each experiment, mice were sacrificed and the tumors were excised 
and weighed.   
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Fig. 2 (A) The retention of GdIONPs in the TRAMP-C1 tumor shown by T1 and 
T2-weighted MR imaging taken at different times. The injected GdIONPs were 
remained in the TRAMP-C1 tumors (highlighted by the yellow outline) for 10, 30, 
and 50 mins. (B) The temperature distribution profile changes across heating time 
measured by a thermocouple needle at the GdIONP injection site. The 
thermotherapy was conducted by an induction heating at an external alternating 
magnetic field (AMF, 52 kHz and 246 Oe) for 40 mins. Mice were injected with 
PBS (AMF only) or GdIONP (AMF+NP) under external alternating magnetic field 
(AMF). (C) The simulated temperature distribution within tumor. The tumor 
temperature decreased by 1.5-degree Celsius for every 2 mm away from the TT 
core.  
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Fig. 3 H & E and PIMO staining of tumor of control (A and C) and thermotherapy 
(B and D) 1 day (A and B) and 1 week (C and D) after treatment. The percentage 
of necrosis (E) and hypoxia (F) of the control and thermotherapy (TT)-treated 
TRAMP-C1 tumors at day one and week one after TT.  The largest cross section of 
the TRAMP-C1 tumor was used to normalize the necrosis and hypoxia areas. 
Necrosis region were delineated by the yellow outlines. The pimonidazole (PIMO) 
was administrated i.v. injection for detecting hypoxia.  Bars indicate the SE of 3 to 
5 tumors at each time point. The hypoxia fraction was defined as the area positive 
of pimonidazole divided by the total tumor area (necrosis excluded). *: P <0.05. 
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Fig. 4 (A) The distribution of necrosis denoted by N, hypoxia stained by PIMO 
(green colour), and vasculature stained by CD31 (red colour) in control and TT 
treated TRAMP-C1 tumors at 1 day and 1 week after treatment. The scale Bar 
equals 100 μm (B) The change of MVD in hypoxic and nonhypoxic regions of the 
control and TT-treated TRAMP-C1 tumors at day one and week one after TT is 
shown as a bar graph. MVD was defined by the percentage of CD31+ area to the 
total tumor in field of view.  The Bars indicate the SE of measurements from 5 
fields (non-necrotic areas) of 3 to 5 tumors for each time point. 
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Fig. 5 (A) hypoxia (green), vasculature (red), and nuclei (blue) areas revealed by 
immunofluorescence staining for the control (10 days), RT (15 days), TT (15 days), 
and combined therapy (15 days) treated TRAMP-C1 tumors. The change of (B) 
necrosis, (C) hypoxia, and (D) MVD in hypoxic and nonhypoxic regions of control 
and TT-treated tumors were represented using a bar graph. There was almost no 
vasculature in the hypoxia regions of irradiated tumors (RT and combined 
therapy). Bar: SE of 5 fields (non-necrotic areas) of 3 to 5 tumors for each time 
point. 
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Supplementary material 
 
Gadolinium-doped iron oxide nanoparticles (GdIONP) synthesis 
 
The Gd-doped iron oxide nanoparticles (GdIONP) were synthesized under an argon 
atmosphere. The standard procedure is outlined below. A reaction flask was charged 
with FeCl2 (0.0345 moles), FeCl3 (0.069 moles) and deionized water (150 ml). To 
produce the Gd-doped sample FeCl3 was replaced by the appropriate amount of GdCl3. 
NaOH with a concentration of 5 M was added to control the pH value of the mixture. 
The mixture was subjected to continuous stirring during the reaction until the mixture 
became basic (the pH value approached 11.5). The temperature of the mixture was then 
raised to 65 °C for 10 min. The black precipitate formed was washed with deionized 
water and the pH adjusted to below 5 with glacial acetic acid. Finally, H2O2 (10 vol %) 
was gradually added until no further reaction occurred. This was judged as the point at 
which no further effervescence occurred on addition of fresh H2O2 followed by a 
deionized water wash. Note that before the precipitates were formed all procedures were 
performed under argon. 
 
The nanoparticle synthesis produced very stable dispersions with no obvious 
precipitation after several days. The appearance of the GdIONP was identical to the 
standard IONP. The magnetic properties were determined with a vibrating sample 
magnetometer (VSM). From the magnetisation curve shown in Fig. S1 it can be seen 
that the GdIONPs are superparamagnetic with a magnetisation value (Ms) of 65.67 emu 
g
-1
. Elemental analysis by ICP-AES confirmed the presence of the Gd and gave atomic 
ratios of 0.007: 1 (Gd : Fe). From this it can be estimated that 25% of the Gd
3+
 present 
in the reaction mixture was incorporated into the final particles giving a particle 
composition of Gd0.02Fe2.98O4. The X-ray diffraction (XRD) spectrum can be seen in 
Fig. S2. This shows that the GdIONP retains the magnetite lattice structure of Fe3O4. 
The reflection from the 311 lattice face can be used to estimate the average crystallite 
size by applying the Scherrer model, this can be written as d = 0.9/cos, where  = 
0.154 nm for the CuKa line, d is the crystallite diameter  is the full width at half 
maximum of the 311 peak in radians and h is the peak position. Applying this formula 
to the spectrum shown in Fig. S2 gives an average crystallite size of 13 nm. The TEM 
image of the nanoparticles can be seen in Fig. S3. This shows the particles have distinct 
lattice faces characterised by cubic or rhombus features with a high degree of 
crystallinity. The average particle size calculated from image analysis is 13.2 ± 3.1 nm, 
this is in good agreement with the average crystallite size estimated from the XRD data. 
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Fig. S1: magnetisation curve for the GdIONPs 
 
 
 
 
Fig. S2: X-ray diffraction spectrum for the GdIONPs 
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Fig. S3: TEM image of the GdIONPs 
 
 
 
Fig. S4: schematic representation of the injection and therapy protocols. For mice 
receiving two injections of either nanoparticles or saline solutions for the blank 
control group, the 1st injection were conducted at the start of treatment or after 
RT, and the 2nd injection were carried out 16 hours after the 1st injection. 
